 Patent Application Title |
Patent App Num. |
Date |
 Microfluidic assay in idealized microvascular network for characterization of leukocyte adhesion cascade | 20130149735 | 20130613 |
 Methods of assaying the leukocyte adhesion cascade (LAC) and monitoring leukocyte rolling, adhesion, and/or migration can be implemented with an apparatus that includes an idealized microvascular network (IMN) of one or more interconnected idealized flow channels in fluid communication through a porous wall with a tissue space (e.g., idealized tissue space). The methods of assaying the LAC can be implemented with means for quantifying modulation of the leukocyte adhesion cascade. Methods of assaying the LAC can be implemented with the device and one or more active agents to monitor leukocyte rolling, adhesion, and/or migration in the presence of absence of the active agent. Migration can be through the idealized flow channels, through the porous wall, and/or into the tissue space.
... |
| Compositions and methods for leukocyte differential counting | 20130137135 | 20130530 |
 The present invention provide compositions and methods for classifying leukocytes in a leukocyte population using fluorescence detection. The methods include contacting a leukocyte population in a sample having one or more leukocyte types with a diagnostic composition, exciting the leukocyte population with a light source; and measuring emitted light from each of the one or more leukocyte types to classify the leukocyte population.
... |
| Pyridin-2yl sulfanyl acid esters and process for the preparation thereof | 20130131350 | 20130523 |
 The present invention relates to Pyridin-2-yl sulfanyl acid ester compounds having antiinflammatory properties. The present invention particularly relates to novel anti-inflammatory heterocyclic acid esters of Pyridin-2-yl sulfanyl having the structure of general formula 1 which have been screened for their antiinflammatory activity with respect to inhibition of adhesion of neutrophils, isolated from human peripheral blood, onto the surface of human umbilical vein endothelial cells (HU-VEC) as a result of inhibition of the cytokine-stimulated expression of cell adhesion molecule ICAM-1. The compound RS—Z, 3-(Pyridin-2-yl sulfanyl)-propionic acid pentyl ester (structure 1a, R1=H, R2=H, R3=CH2-COOC5H11) was found to be most effective for ICAM-1 and neutrophil adhesion inhibition and was found to effectively alleviate inflammation mediated by excessive leukocyte infiltration leading to inflammatory disorders or like conditions, such as acute... |
| Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | 20130116266 | 20130509 |
 Compounds that inhibit P13Kδ activity, including compounds that selectively inhibit P13Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13Kδ plays a role in leukocyte function, using the compounds also are disclosed.
... |
| Multimeric fc receptor polypeptides | 20130089893 | 20130411 |
 A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fcγ receptors (FcγR) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an FcγR type receptor and, particularly, FcγRIIa. Also described are polynucleotide molecules encoding the protein or polypeptide and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.
... |
Subscribe to updates on this page: Leukocyte RSS  |
| Activated leukocyte composition and uses for wound healing | 20130071465 | 20130321 |
| Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.
... |
| Pharmaceutical composition containing choline | 20130058922 | 20130307 |
| The invention further relates to pharmaceutical compositions, in particular for intravenous administration, containing choline or pharmaceutically acceptable salts or analogues thereof, alone or in combination with vitamin C and/or L-arginine and/or vitamin D3 (cholecalciferol) for use in the fight against CTCs, DTCs or dysfunctional leukocyte precursors in the blood or bone marrow.
... |
| Therapeutic uses of humanized antibodies against alpha-4 integrin | 20130059337 | 20130307 |
| The invention provides method of treatment using humanized immunoglobulins that specially bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
... |
| Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device | 20130047861 | 20130228 |
| A blood filter device comprising: a housing comprising an outer wall and a first inlet, a first outlet and a second outlet; a membrane which is capable of separating plasma from the blood, wherein the membrane forms an inner chamber; a leukocyte and oxygen and/or carbon dioxide depletion media disposed wherein the inner chamber, the leukocyte and oxygen and/or carbon dioxide depletion media is capable of depleting leukocytes and oxygen and/or carbon dioxide from the blood; an outer chamber disposed between the outer wall and the membrane, wherein the plasma which permeates through the membrane enters the outer chamber and exits the filter device via the first outlet; whereby the blood which has been depleted of oxygen and/or carbon dioxide, leukocytes and plasma exists and filter... |
| Compounds for modulating integrin cdiib/cdi8 | 20130045967 | 20130221 |
| The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
... |
| Modulation of plasma membrane human leukocyte elastase | 20130017601 | 20130117 |
| A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein.
... |
| Inhibition of leukocyte adhesion | 20120328632 | 20121227 |
| This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.
... |
| Multimeric vla-4 antagonists comprising polymers moieties | 20120329807 | 20121227 |
| Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
... |
Subscribe to updates on this page: Leukocyte RSS |
| Human monoclonal antibody that specifically binds to vcam-1 and a composition for treating an inflammatory disease or a cancer comprising the same | 20120308574 | 20121206 |
| The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.
... |
| Magnetic beads for reducing leukocyte interference in immunoassays | 20120295290 | 20121122 |
| Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.
... |
| Compositions and methods for bioactive coatings to improve allograft incorporation | 20120213837 | 20120823 |
| The invention provides compositions and methods useful for treating wounds and enhancing wound healing. The present invention discloses a continuous polymer coating system to provide sustained localized delivery of bioactive agents. The data demonstrate the efficacy of a bioactive coating comprising the polymer PLAGA and the agent FTY720, a selective agonist for sphingosine 1-phosphate receptors, and biologically active derivatives and analogs thereof, for use in wound healing. In vitro drug release studies validated 64% loading efficiency with complete release of compound following 14 days. Mechanical evaluation of healing bone showed significant enhancement of mechanical stability in FTY720 treatment groups. Superior osseous integration across the host-graft interface, significant enhancement in smooth muscle cell investment, and reduction in leukocyte recruitment were evident in FTY720 treated groups. The present... |
| Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use | 20120171195 | 20120705 |
| Provided herein are compositions comprising antibodies immunoreactive to human leukocyte antigen E (HLA-E) and HLA Ia alleles, methods of their use, for example, as therapeutic IVIg mimetics, methods of their preparation and methods of their immunomodulatory benefits and applications. In particular embodiments provided herein are compositions and methods for treating an inflammatory condition or graft rejection.
... |
| Inhibitors of human phosphatidylinositol 3-kinase delta | 20120172591 | 20120705 |
| Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.
... |
| Methods, reagents and kits for flow cytometric immunophenotyping | 20120165213 | 20120628 |
| The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.
... |
| Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders | 20120148586 | 20120614 |
| Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies.
... |
| Inhibitors of human phosphatidylinositol 3-kinase delta | 20120135994 | 20120531 |
| Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.
... |
| Component preparation system | 20120111807 | 20120510 |
| Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system.
... |
| Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or class ii molecules for vaccines | 20120107337 | 20120503 |
| The present invention relates to novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumour immune responses.
... |
| Prophylactic or therapeutic agent for rheumatoid arthritis or rheumatoid arthritis-related diseases | 20120094914 | 20120419 |
| (b) A protein consisting of the amino acid sequence of SEQ ID NO: 1 with the deletion, substitution, or addition of one or several amino acids excluding the amino acid at position 42, and having a binding activity for leukocyte Ig-like receptors and/or CD8
... |
| Software integrated cytometric assay for quantification of the human polymorphonuclear leukocyte fcyri receptor (cd64) | 20120084013 | 20120405 |
| The invention relates a method of quantifying CD64 and CD163 expression in leukocytes and, specifically to a kit for use with a flow cytometer including a suspension of quantitative fluorescent microbead standards, fluorescent labeled antibodies directed to CD64 and CD163, and analytical software. The software is used to take information on the microbead suspension and fluorescent labeled antibodies from a flow cytometer and analyse data, smooth curves, calculate new parameters, provide quality control measures and notify of expiration of the assay system.
... |
| Filter medium for leukocyte removal | 20120067821 | 20120322 |
| The present invention discloses a filter medium for removing leukocytes from a leukocyte-containing sample, comprising: a substrate and a first polymer. The first polymer forms cross-linked networks or polymer brushes on the substrate and comprising charged groups or latent charged groups to control the electrical characteristic of the first polymer. The surface of the substrate formed with the first polymer possesses a specific charge distribution having charged domains and zwitterionic non-charged domains.
... |
| Solid forms of a chemokine receptor antagonist and methods of use thereof | 20120065223 | 20120315 |
| The citrate salt of (S)-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol, which may be used in pharmaceutical applications, is disclosed. The crystalline Citrate Salt, including particular single crystal forms and combinations of the single crystalline forms, are also discussed. Mixtures for forming the crystalline salts are discussed. As well, methods of producing the Citrate Salt, and crystalline forms thereof, and using such Citrate Salt, and crystalline forms thereof, in treating diseases associated with aberrant leukocyte recruitment, activation, or recruitment and activation are also discussed.
... |
| Filter method for separating unbound ferrofluid from target-bound ferrofluid in a biological sample | 20120055854 | 20120308 |
| A filtering system for separating unbound ferrofluid from bound ferrofluid in the enrichment of a target entity in a biological sample. The filtering device of the present invention has application in the isolation target cells from unbound ferrofluid during separation with a permanent magnet (floater) mechanism. This process reduces interference of unbound ferrofluid during subsequent image analysis or enumeration of cells by image cytometry. The system has application in the assessment of target populations such as leukocyte subsets in different bodily fluids or bacterial contamination in environmental samples, food products and bodily fluids. Briefly, fluorescently labeled target cells are linked to magnetic particles or beads. The linkage process results in a mixture having a population of contaminating unbound magnetic particles. In one embodiment for separation, a... |
| Activated leukocyte composition and uses for wound healing | 20120058156 | 20120308 |
| Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.
... |
| Separation of antigen-specific memory b cells with a conjugated biopolymer surface | 20120045827 | 20120223 |
| The present invention provides materials and methods for the isolation of immune cells. In one embodiment, the present invention provides a device for the isolation and separation of antigen-specific memory B cells. Immune cells will be separated by flowing the cells along a ligand-conjugated biopolymer surface. The ligand may be distributed in a concentration gradient along the z-axis of the biopolymer surface. Cells that display receptors specific for the ligands on the biopolymer will interact with the ligands and roll along the surface in the fashion of leukocyte rolling. Additive adhesive interactions will cause differential cell separation and eventual immobilization.
... |
| Method and apparatus for imaging target components in a biological sample using permanent magnets | 20110014686 | 20110120 |
| A system for enumeration of cells in fluids by image cytometry is described for assessment of target populations such as leukocyte subsets in different bodily fluids or bacterial contamination in environmental samples, food products and bodily fluids. Briefly, fluorescently labeled target cells are linked to magnetic particles or beads. In one embodiment, a small, permanent magnet is inserted directly into the chamber containing the labeled cells. The magnets are coated with PDMS silicone rubber to provide a smooth and even surface which allows imaging on a single focal plane. The magnet is removed from the sample and illuminated with fluorescent light emitted by the target cells captured by a CCD camera. In another embodiment, a floater having a permanent magnet allows the target cells to line... |
| Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof | 20110009597 | 20110113 |
| Provided are the use of the recombinant Ganoderma lucidium immunomodulatory protein (rLZ-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rLZ-8 protein, wherein the rLZ-8 protein is expressed from pichia yeast.
... |
| Multimeric vla-4 antagonists comprising polymer moieties | 20110002876 | 20110106 |
| Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
... |
| Carboxamide compounds and their use | 20100331298 | 20101230 |
| Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.
... |
| Cyclic peptides as g-protein coupled receptor antagonists | 20100331236 | 20101230 |
| The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.
... |
| Carboxamide compounds and their use | 20100324035 | 20101223 |
| Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.
... |
| Pyrimidine derivatives useful for the treatment of diseases mediated by crth2 | 20100322980 | 20101223 |
| The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive... |
| Novel triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents | 20100317606 | 20101216 |
| This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer,... |
| Probes | 20100317004 | 20101216 |
| The present invention relates to probes, methods and apparatus for the detection of the presence or absence of non-contiguous cis-located nucleic acid sequences which are characteristic of alleles including those relating to the human leukocyte antigen (HLA) which is of interest in the field of human transplantation and disease.
... |
| Novel peptides | 20100316569 | 20101216 |
| This invention relates to novel peptides, discovered by using phage display technique, that bind to VAP-1 (Vascular Adhesion Protein-1). The invention concerns also peptides useful as VAP-1 ligands. Such peptides constitute a portion of natural proteins that are present in the individual. The invention relates particularly to a peptide chain in the leukocyte surface protein, where said peptide chain is useful as a ligand for the VAP-1 molecule and thus facilitates the binding of leukocytes to the vascular endothelium. Furthermore, the invention relates to pharmaceutical and diagnostic compositions for targeting VAP-1 in vivo.
... |
| Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof | 20100286064 | 20101111 |
| The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.
... |
| Biological fluid filtration apparatus | 20100282681 | 20101111 |
| Biological fluid filtration systems including biological fluid filtration devices capable of filtering blood or blood products, including the removal of leukocytes from the blood or blood product. Each system includes a means to automatically drain the biological fluid upstream of the biological fluid filtration media disposed in the biological fluid filtration device. Both single sided and double sided biological fluid filtration devices are disclosed, including double sided biological fluid filtration devices with a solid partition wall with a first independent fluid flow path on one side of the partition wall, and a second independent fluid flow path on the other side of the partition wall. Draining means include vent filtration devices, diaphragm draining devices, and biological fluid filtration devices that include an integral diaphragm. The biological... |
| Enhanced fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis | 20100279296 | 20101104 |
| A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.
... |
| Method for assessing potential for tumor development and metastasis | 20100272651 | 20101028 |
| The present invention generally provides methods for assessing the potential of tumor formation and/or metastasis using a combination (e.g., a ratio) of the number of circulating tumor cells and the number of circulating cells exhibiting autofluorescence within a selected wavelength region (e.g., red autofluorescence). In one aspect, it is directed to a method for providing likelihood of occurrence of a primary and/or a metastatic cancerous tumor in an animal, which comprises inoculating the animal with a plurality of cancer cells, determining a ratio of a number of cancer cells relative to a number of circulating indicator cells (e.g., immature leukocytes) that exhibit autofluorescence in the inoculated animal's blood and correlating the ratio to a likelihood that the animal will develop at least one primary and/or metastatic... |
| Selective cytopheresis devices and related methods thereof | 20100268147 | 20101021 |
| The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.
... |
| Selective cytopheresis devices and related methods thereof | 20100268146 | 20101021 |
| The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.
... |
| 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | 20100267726 | 20101021 |
| Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
... |
| Treatment of osteoarthritis | 20100267639 | 20101021 |
| This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed.
... |
| Genotoxicity as a biomarker for inflammation | 20100267037 | 20101021 |
| The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory... |
| Selective cytopheresis devices and related methods thereof | 20100266562 | 20101021 |
| The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.
... |
| Selective cytopheresis devices and related methods thereof | 20100266563 | 20101021 |
| The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.
... |
| Imidazole compounds | 20100261899 | 20101014 |
| Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Imidazole compounds | 20100261898 | 20101014 |
| Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 | 20100261715 | 20101014 |
| Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
... |
| Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | 20100256168 | 20101007 |
| Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.
... |
| Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | 20100256167 | 20101007 |
| Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.
... |
| Stimulation of neuron regeneration by secretory leukocyte protease inhibitor | 20100256065 | 20101007 |
| The present invention provides methods for stimulating neuronal survival, growth and regeneration by administering SLPIs to animals, such as humans. These methods can be used to treat a variety of neurological conditions such as neural injuries and degenerative diseases in subjects in need thereof.
... |
| Novel ligand involved in the transmigration of leukocytes across the endothelium and uses therefor | 20100249383 | 20100930 |
| The present invention provides methods and compositions involved in the inflammatory response, as well as various pathological processes. In particular, the present invention provides novel antibodies directed against novel glycans that are enriched on endothelial cell surfaces. In addition, the present invention provides methods and compositions involved in a previously unrecognized pathway of the inflammatory response and various pathological processes. In addition the present invention provides methods and compositions suitable to mediate the inflammatory response in various settings, as well as methods and compositions for the identification of other inflammatory response mediators.
... |
| Hla peptide therapy | 20100215619 | 20100826 |
| The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection.
... |
| Carboxamide compounds and their use | 20100210633 | 20100819 |
| Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.
... |
| Leukocyte cell banks | 20090324567 | 20091231 |
| The invention relates to a novel form of leukapheresis (isolated leukapheresis), to processes and apparatus for carrying out isolated leukapheresis, to leukocyte cell banks created thereby and to various forms of therapy based thereon.
... |
| Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis | 20090311684 | 20091217 |
| A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of TNFSF-3, TNFSF-4, TNFSF-7, TNFSF-11, or TNFSF-14 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.
... |
| Interfering in activation of an immune cell by influencing interaction of lair and collagen | 20090304686 | 20091210 |
| The invention provides a method for interfering in activation of an immune cell, comprising providing a substance which specifically interacts in the binding of leukocyte-associated immunoglobulin-like receptor (LAIR) and collagen. The invention in one aspect provides a method for down regulation of activation of an immune cell. In another aspect the invention provides a method for up regulation of activation of an immune cell. The invention further provides pharmaceutical compositions and uses thereof.
... |
| Methods for the treatment and prevention of infection using anti-selectin agents | 20090304681 | 20091210 |
| Methods for the treatment and prevention of pulmonary infections are disclosed, in particular, methods comprising the administration of one or more anti-selectin agents to a patient diagnosed with a pulmonary infection. Anti-selectin agents that inhibit leukocyte recruitment to the lungs have been found to be beneficial for the treatment of lung infections, including infections associated with chronic bronchitis, chronic obstructive pulmonary disease (COPD), pneumonia, pneumonitis, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), sarcoidosis, cystic fibrosis (CF), emphysema, asthma, smoker's cough, allergy, allergic rhinitis, sinusitis and pulmonary fibrosis.
... |
| Filter for the removal of substances from blood products | 20090301957 | 20091210 |
| A filter for the removal of substance from blood or blood components, particularly for the removal of leukocytes and platelets, comprises a polymeric filter material having a polyurethane coating, wherein the polyurethane has a number average molecular weight not higher than 10,000 Da; the polyurethane is preferably obtained by the addition reaction of an aliphatic diisocyanate, polyethylene glycol and butandiol, by using an excess of the butandiol, whereby the addition reaction is stoichiometrically unbalanced.
... |
| Compositions and methods for treating cerebral thrombosis and global cerebral ischemia | 20090291086 | 20091126 |
| Modified annexin proteins, including heterodimers and homodimer of various human annexins, are provided for treatment of cerebral thrombosis and global cerebral ischemia. Also provided are phosphatidylserine (PS) binding proteins for treatment of cerebral thrombosis and global cerebral ischemia. The modified annexins and/or PS binding proteins bind PS on cell surfaces, thereby preventing the attachment of leukocytes and platelets to endothelial cells during post-ischemic reperfusion. By maintaining endothelial cell and vascular wall integrity PS binding proteins and/or modified annexin proteins decrease cerebral hemorrhage. Modified annexins and other PS binding proteins also suppress the production of mediators of edema, the extension of cerebral damage during reperfusion and the risk of rethrombosis. Thus, modified annexin proteins and/or other PS binding proteins decrease brain damage following cerebral thrombosis and global... |
| Leukocyte-binding polypeptides and uses thereof | 20090291048 | 20091126 |
| The present invention provides molecules capable of specifically binding the activated form of the beta-integrin Mac-1. The molecules may be provided in the form of peptides, polypeptides and single chained antibodies. The molecules may be used therapeutically for the treatment of disease mediated by Mac-1 (such as inflammation), or used diagnostically to locate sites of Mac-1 activity in the body.
... |
| Device comprising a container system for a bodily fluid | 20090286221 | 20091119 |
| The invention relates to a device for separating a bodily fluid, in particular blood platelet concentrate, into fractions under centrifugal force. The device comprises a flexible container system which comprises at least a first container for the fluid to be separated and a second container for a separated fraction, wherein the containers are mutually connected using a connecting conduit for a fluid, wherein a widened portion is arranged in the connecting conduit between the first and second container, wherein during use a detectable separating layer is created in the widened portion. The invention also relates to a flexible container system intended for the device, a method for separating blood platelet concentrate into fractions under centrifugal force, and a blood platelet concentrate with low leukocyte content.
... |
| Anti-psgl-1 antibodies and methods of identification and use | 20090285812 | 20091119 |
| The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof.
... |
| Benzoimidazole compounds | 20090281307 | 20091112 |
| Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Chemokine receptor antagonists and methods of use therefor | 20090281081 | 20091112 |
| or physiologically acceptable salt thereof.
... |
| Benzoimidazole compounds | 20090281307 | 20091112 |
| Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Chemokine receptor antagonists and methods of use therefor | 20090281081 | 20091112 |
| or physiologically acceptable salt thereof.
... |
| Absorbent and column for extracorporeal circulation | 20090275874 | 20091105 |
| The present invention provides an absorbent which can remove cells present in blood including activated leukocytes such as granulocytes and monocytes, and cancer cells as well as can remove cytokines which facilitate the activation of the remaining cells, and further has no concern for pressure loss and has high configuration stability. That is, the present invention provides an absorbent which absorbs the granulocytes and the monocytes in blood, an absorbent for cancer therapy which absorbs an immunosuppressive protein and an absorbent having a bilayer structure of a net and a nonwoven fabric, having a zeta potential of −20 mV or more, as well as a blood circulation column containing any of the absorbents filled therein.
... |
| Benzoimidazole compounds | 20090275748 | 20091105 |
| Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Method of determining chymase activity with secretory leukocyte protease inhibitor | 20090275068 | 20091105 |
| It is now discovered that human chymase cleaves human SLPI at a specific site and that this cleavage can be used as an indicator of chymase activity. The present invention provides methods of diagnosing a chymase-associated disease or evaluating the efficiency of a treatment of a chymase-associated disease in a human subject by measuring SLPI processing, as well as other related methods and compositions.
... |
| Monoclonal antibodies specific to denatured human class i leucocyte antigens | 20090275055 | 20091105 |
| [MEANS FOR SOLVING THE PROBLEMS] It was discovered that injection of denatured recombinant HILA-A*2402 heavy chain proteins to mouse for immunization led to establish HLA class I-specific antibody binding all of denatured HLA-A, B and C. The present invention is a monoclonal antibody specifically binding HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens, wherein said monoclonal antibody is produced by hybridomas (FERM AP-20454) and bound specifically HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens. Furthermore, the present invention is a test reagent for examining denatured human class I leukocyte antigens containing the monoclonal antibody as a major component.
... |
| Compositions comprising hypsizygus ulmarius extract | 20090274721 | 20091105 |
| Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1β mediated adhesion of polymorphonuclear leukocytes. The Hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1β mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmarius extract in a defined treatment regimen.
... |
| Tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine | 20090274714 | 20091105 |
| The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines, which can be used in vaccine compositions for eliciting anti-tumour immune responses.
... |
| Absorbent and column for extracorporeal circulation | 20090275874 | 20091105 |
| The present invention provides an absorbent which can remove cells present in blood including activated leukocytes such as granulocytes and monocytes, and cancer cells as well as can remove cytokines which facilitate the activation of the remaining cells, and further has no concern for pressure loss and has high configuration stability. That is, the present invention provides an absorbent which absorbs the granulocytes and the monocytes in blood, an absorbent for cancer therapy which absorbs an immunosuppressive protein and an absorbent having a bilayer structure of a net and a nonwoven fabric, having a zeta potential of −20 mV or more, as well as a blood circulation column containing any of the absorbents filled therein.
... |
| Benzoimidazole compounds | 20090275748 | 20091105 |
| Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Method of determining chymase activity with secretory leukocyte protease inhibitor | 20090275068 | 20091105 |
| It is now discovered that human chymase cleaves human SLPI at a specific site and that this cleavage can be used as an indicator of chymase activity. The present invention provides methods of diagnosing a chymase-associated disease or evaluating the efficiency of a treatment of a chymase-associated disease in a human subject by measuring SLPI processing, as well as other related methods and compositions.
... |
| Monoclonal antibodies specific to denatured human class i leucocyte antigens | 20090275055 | 20091105 |
| [MEANS FOR SOLVING THE PROBLEMS] It was discovered that injection of denatured recombinant HILA-A*2402 heavy chain proteins to mouse for immunization led to establish HLA class I-specific antibody binding all of denatured HLA-A, B and C. The present invention is a monoclonal antibody specifically binding HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens, wherein said monoclonal antibody is produced by hybridomas (FERM AP-20454) and bound specifically HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens. Furthermore, the present invention is a test reagent for examining denatured human class I leukocyte antigens containing the monoclonal antibody as a major component.
... |
| Compositions comprising hypsizygus ulmarius extract | 20090274721 | 20091105 |
| Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1β mediated adhesion of polymorphonuclear leukocytes. The Hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1β mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmarius extract in a defined treatment regimen.
... |
| Tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine | 20090274714 | 20091105 |
| The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines, which can be used in vaccine compositions for eliciting anti-tumour immune responses.
... |
| Benzoimidazole compounds | 20090270613 | 20091029 |
| Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Benzoimidazole compounds | 20090270611 | 20091029 |
| Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Benzoimidazole compounds | 20090270366 | 20091029 |
| Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Method for screening peptides for use in immunotherapy | 20090269363 | 20091029 |
| Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then... |
| Method for screening peptides for use in immunotherapy | 20090269363 | 20091029 |
| Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then... |
| Compositions containing a capillary -active system with application -relevant differentiability, and the use thereof | 20080317856 | 20081225 |
| The invention also relates to the use of such compositions, in particular systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components), or pharmaceutical agents.
... |
| Inhibition of infiltration, and cell killing agent | 20080318297 | 20081225 |
| As suppressor of binding between selectin binding sugar chain and selectin or cell killing agent, (1) siRNA suppressing expression of genes which relates to cell surface antigen CD43 and selectin ligand sugar chain by RNA interference; (2) an inhibitor of sugar chain synthesis such as analogue of substrates in sugar chain synthesis; (3) an enzyme severing cell surface antigen CD43 and selectin ligand sugar chain; and (4) antibodies of cell surface antigen CD43 and selectin ligand sugar chain are used to selectin ligand sugar chain expressed in cell surface antigen CD43 to provide a suppressor of infiltration which is able to suppression of infiltration to tissues by leukocytes and a method of suppression thereof, and a cell killing agent of CD43 expressing cell and a cell... |
| Nucleic acid fragments for detecting nucleic acid and method for detecting nucleic acid | 20080311571 | 20081218 |
| A nucleic acid fragment set according to the present invention comprises a plural number of nucleic acid fragments capable of individually hybridizing with a plural number of target sequences, in which each nucleic acid fragment has a region ligatable with each other and the affinity between such ligatable regions is adjusted to a higher level than the affinity between the target sequence and the nucleic acid fragment. The nucleic acid fragment according to the present invention is for use in a nucleic acid fragment kit. The nucleic acid fragment of the present invention can be used as a probe for detecting nucleic acid or a competitor for detecting nucleic acid. According to the present invention, human leukocyte antigen (HLA) genes, T-cell receptor genes, red blood cell... |
| Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases | 20080305046 | 20081211 |
| This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (DR) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser opthalmoscope. In other embodiments, the invention relates to targeted delivery of drugs or other substances to specific regions of an intraluminal surface of a blood vessel using drug-containing microparticles coated with one or more ligand binding partners.
... |
| Pharmaceutically active diazepanes | 20080300237 | 20081204 |
| Leukocyte Function-Associated Antigen One (LFA-1) is a cell adhesion molecule selectively expressed on leukocytes, and plays a major role in the activation and trafficking of T lymphocytes in the tissue at sites of inflammation. In the last decade a large body of preclinical data has accumulated to establish the importance of LFA-1 as a biological target, 10 particularly in chronic, T-cell driven inflammatory conditions. The present invention provides pharmaceutically active 1,4-diazepan-2-ones of formula I useful for the treatment of conditions related to LFA-1 activity.
... |
| Leukocyte inactivation module | 20080292643 | 20081127 |
| The present invention provides a module for reducing the activity of leukocytes which comprises a carrier and a ligand that is linked to the carrier and is suitable for interacting with a leukocyte receptor. Furthermore, the present invention provides a process for reducing the activity of leukocytes using said module. The advantage of the present invention is that after binding the activated leukocytes in the leukocyte inactivation module (LIM), the damaging effect of the cells is inhibited within minutes.
... |
| Single population of simulated leukocyte granules, calibrators comprising the same and methods of preparing the same | 20080293145 | 20081127 |
| The present invention discloses a single population of simulated leukocyte granules prepared from mammalian whole white blood cells, which is useful in calibrators for a hematology analyzer, a calibrator comprising the single population of simulated leukocyte granules, and a method of preparing the single population of simulated leukocyte granules. The method of preparing single population of simulated leukocyte granules according to present invention comprises the steps of: obtaining mammalian whole white blood cells; treating the mammalian whole white blood cells under the action of a hemolytic agent in the presence of a leukocyte treating liquid, i.e., an isotonic saline solution comprising a fixative, a oxidizer and a carbohydrate; fixing the treated mammalian whole white blood cells with a fixative; and suspending the fixed cells in a... |
| Fused heterocyclic compounds and use thereof | 20080293650 | 20081127 |
| wherein R1, R2, R5, Z, J1 and J2 are described herein, and analogs thereof are provided which are useful in treating leukocyte activation-associated disorders.
... |
| System and method for the management or control of cardiovascular related diseases, such as hypertension | 20080294021 | 20081127 |
| A system and a method for the management or control of cardiovascular related diseases, in particular of hypertension, basically comprises a blood pressure measuring device and means for determining an activity status of the autonomic nervous system. In particular, this status is determined on the basis of heart rate variability or on the basis of a composition ratio of granulocytes and lymphocytes in leukocytes of the individual.
... |
| Compositions comprising hypsizygus ulmarius extract | 20080286298 | 20081120 |
| Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1β mediated adhesion of polymorphonuclear leukocytes. The hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1β mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmarius extract in a defined treatment regimen.
... |
| Modifying leukocyte function | 20080286304 | 20081120 |
| Use of PREPS and/or L-particles for the manufacture of a medicament for modifying or regulating leukocyte function.
... |
| Blood sample handling methods for improved assays for myeloperoxidase | 20080286818 | 20081120 |
| The invention provides a method for determining concentration of myeloperoxidase (MPO) in a human blood sample comprising: (a) providing a human peripheral blood sample stored under MPO preservation conditions; and (b) determining concentration of MPO in a plasma sample derived from the human peripheral blood sample. In a preferred embodiment, the MPO preservation conditions used in the invention comprise storage of the human peripheral blood sample in a plasma collection tube containing a leukocyte MPO secretion inhibitor. In this embodiment, the leukocyte MPO secretion inhibitor is preferably ethylene diamine tetraacetic acid (EDTA). The assays used in the inventive methods can comprise any clinically useful assay for determining MPO plasma concentration, including sandwich and competitive immunoassays, clinical chemistry assays and enzymatic assays.
... |
| Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation | 20080287469 | 20081120 |
| The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting leukocyte accumulation comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) and phosphoinositide 3-kinase gamma (PI3Kγ) activities in endothelial cells. The disclosed methods may be used to treat individuals having an inflammatory condition where leukocytes are found to be accumulating at the site of insult or inflamed tissue. The inflammatory condition may be attributed to or associated with an underlying disorder not typically associated with inflammation, e.g. cancer, coronary vascular disease, etc.
... |
| Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | 20080275067 | 20081106 |
| Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.
... |
| Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof | 20080267958 | 20081030 |
| A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.
... |
| Polyethylene oxide polymers including anti-inflammatory glycodendrons | 20080268013 | 20081030 |
| Poly(ethylene oxide) (PEO) glycodendrimers can serve as multivalent inhibitors of selectin-mediated leukocyte recruitment regulating inflammatory response. Disclosed are compounds and methods relating to functionalized branched glycopolymers. In embodiments, the compounds are capable of modifying cell adhesion events and inflammatory conditions. In a particular embodiment, a multi-arm PEO polymer with sulfated lactose end groups can specifically inhibit interactions involving L-selectin. Also disclosed are methods of synthetic preparation and use.
... |
| Method for suppressing surgical site infection and column to be used for the method | 20080260710 | 20081023 |
| An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method. According to the present invention, a method is provided for suppressing surgical site infections, which comprises the steps of: (a) administering a chemotherapeutic drug for treating and/or preventing a surgical site infection; and (b) collecting blood from a surgical subject and removing leukocytes that comprise neutrophils from the blood during or within 24 hours after surgical operation, and then returning the blood from which the leukocytes have been removed to the surgical subject. The present invention... |
| Diagnostic device and method | 20080248582 | 20081009 |
| A method of separating a cell-containing sample into a substantially cell-depleted portion, and a cell-containing portion comprising at least one of a stem cell, a lymphocyte, and a leukocyte comprises a step in which the sample is received in a vessel with at least one flexible wall. In another step, an additive and particles are added to the sample, wherein the additive substantially binds to the at least one of the stem cell, lymphocyte, and leukocyte, and the particles and wherein the particles substantially bind to the at least one of the stem cell, lymphocyte, and leukocyte, and the additive, thereby producing a cell-containing network. In a further step, the network is separated from the substantially cell-depleted portion by applying a magnetic force.
... |
| (3,4-disubstituted)propanoic carboxylates as sip (edg) receptor agonists | 20080249093 | 20081009 |
| as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.
... |
| Inhibition of leukocyte adhesion | 20080241143 | 20081002 |
| This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.
... |
| Filter for the removal of substances from blood products | 20080230475 | 20080925 |
| A filter device for the depletion of the leukocyte content from blood products comprising: a porous element comprising at least one fibrous web having a pore size suitable for leukocyte removal (possibly the range for the pore size should be defined), said web comprising fibres of a hydrophobic polymer coated with a hydrophilic polymer suitable to enhance the CWST of said hydrophobic polymer, characterised in that said web further includes adsorbent particles having a mean diameter lower than 30 μm, said particles being bonded to said fibres by means of said hydrophilic polymer coating said fibres.
... |
| Modified peptides and their uses | 20080234176 | 20080925 |
| A modified pro-α chain comprising a triple helix forming domain linked to at least an N-terminal domain, the N-terminal domain containing a polypeptide from at least part of a laminin glycoprotein or secretory leukocyte protease inhibitor. The pro-α chain may form part of a procollagen molecule that has the N-terminal domain retained. The procollagen molecule may be incorporated into collagen polymers, matrices and gels and be used for such applications as wound healing.
... |
| Process for segmenting leukocytes | 20080212868 | 20080904 |
| A method for segmenting stained leukocytes in blood smears includes the following steps: the pixels of the digital images taken of the blood smears are allocated to one of at least three pixel classes according to their chromaticity values; the chromaticity values of all pixels of the image are subjected to the same transformation with which the pixels allocated to the class of the image background appear at least almost white; a transformation of the stained image obtained takes place into an alternative color space, which represents the hue, color saturation and color intensity separately, and hue, color saturation and color intensity of all pixels are ascertained; a probability value is calculated for each pixel for its association to a leukocyte, the probability value corresponding to... |
| Blocking leukocyte emigration and inflammation by interfering with cd99l2 | 20080213279 | 20080904 |
| The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that the adhesion molecule CD99L2 mediates TEM of leukocytes. CD99L2 is present on endothelial cells and leukocytes and mediates leukocyte-endothelial cell adhesion. Blockade of CD99L2 by use of a specific antibody blocks migration of leukocytes into a site of inflammation. CD99L2 shows functional analogy to the structurally-related molecule, CD99, inhibition of which, in conjunction with inhibition of PECAM, causes near total blockade of TEM. Thus, blocking CD99L2 on either endothelial cells or monocytes can block migration 80-90%. In conjunction with PECAM inhibitors, TEM blockade can approach 100%. Therapeutic treatments involving... |
| Method for the elimination of leukocytes from blood | 20080203024 | 20080828 |
| The invention relates to a method for reducing the number of leukocytes in blood through treating the blood in an arrangement of a plurality of fibers based on organic polymers, whereby the blood is channeled along the fibers and whereby the reduction in leukocytes from the blood occurs essentially through adsorption on the fibers, characterized in that the plurality of fibers based on organic polymers is fixed in a housing with an inlet arrangement and an outlet arrangement, and that the blood is channeled via the inlet arrangement into the housing, flows through the housing with the plurality of fibers made from organic polymers, and exits the housing via the outlet arrangement, that the arrangement of the fibers shows a high degree of order, that the... |
| Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules | 20080206216 | 20080828 |
| The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
... |
| Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules | 20080206217 | 20080828 |
| The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
... |
| Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules | 20080206218 | 20080828 |
| The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
... |
| Ex vivo gene expression in whole blood as a model of assessment of individual variation to dietary supplements | 20080206761 | 20080828 |
| A method is disclosed for individually tailoring the administration of dietary components such as supplements. In the method, whole blood of a mammal is exposed to a dietary component. The level of a marker mRNA linked to a disease state is measured in leukocytes after exposure to the dietary component, and in some cases after further stimulation of the exposed blood cells. By comparing the mRNA level after exposure with the value found in unexposed blood cells, it is possible to determine what the effect of the dietary component will be in the mammal. By screening blood of the mammal against a number of possible dietary components, it is possible to develop an optimized set of dietary components tailored to the specific mammal to treat or... |
| Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules | 20080207520 | 20080828 |
| The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
... |
| Composition for treating baldness with stem cell derived from umbilical cord blood | 20070298017 | 20071227 |
| Provided is a therapeutic technique for treating baldness, using an umbilical cord blood-derived stem cell. Transplantation of a composition for treating baldness into a bald area of a patient can make great contributions to treatment for baldness, wherein the composition comprises stem cells isolated and cultured from umbilical cord blood in which 6 HLA (Human Leukocyte Antigen) are identical with a patient, or one or two HLA are not identical with the patient.
... |
| Antibody-based method for isolating th1 and th2 helper lymphocytes from human peripheral blood | 20070298441 | 20071227 |
| A negative isolation method for separately isolating preparations of Th1 and Th2 helper lymphocytes from peripheral blood mononuclear cells involving the use of novel combinations of monoclonal antibodies to separately sequester specific Th1 and Th2 lymphocytes and contaminating leukocytes and erythrocytes, adding a magnetic colloid to the cells, and using a magnetic column for fractionation of Th1 and Th2 cells. Imbalances in the relative numbers of Th1 and Th2 lymphocytes can be used in the diagnosis and prognosis of human diseases.
... |
| Vcam-1 specific monoclonal antibody | 20070280941 | 20071206 |
| The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes... |
| Vaccine and method of use | 20070275013 | 20071129 |
| A therapeutic vaccine is prepared by a method which includes the steps of extracting, with a lipid-extracting solvent, a biological fluid obtained from a person or animal infected with a lipid-containing infectious organism, the biological fluid containing the lipid-containing infectious organism, and the extraction producing an aqueous phase and a lipid-containing phase, said aqueous phase containing the infectious organism with the lipid substantially removed, and separating the aqueous phase from the lipid-containing phase. A leukocyte fraction is isolated from the blood of the person or animal, the isolation being conducted so that the leukocyte fraction is substantially without plasma, free lipid-containing infectious organism and free antibodies to the lipid-containing infectious organism, and at least some of the aqueous phase is combined with at least some of... |
| Device and method for analysis of a metabolic malady | 20070275425 | 20071129 |
| A method for detecting a metabolic malady in a subject, the method including: (a) measuring a quantitative feature of a lipid body disposed within a leukocyte derived from the subject, and (b) comparing the measurement obtained in step (a) with a threshold value, wherein if the measurement is significantly different from the threshold value, the measurement is indicative that the subject has or is at risk of developing the metabolic malady.
... |
| Reagents and methods for classifying leukocytes | 20070275469 | 20071129 |
| The present invention relates to a reagent for classifying leukocytes comprising (a) at least one surfactant capable of lysing erythrocytes and partly damaging the cell membrane of leukocytes, (b) at least one organic compound bearing an anionic group capable of binding to the cationic component present in the leukocytes to provide morphological differences between the leukocytes, (c) a buffer for adjusting pH to 2-8. Also disclosed is a method for classifying leukocytes into four groups.
... |
| Novel chemokine mimetics synthesis and their use | 20070275892 | 20071129 |
| The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example, and can be selected from a group consisting of hematopoietic stem cells, hematopoietic progenitor cells, primitive granulocytes, primitive erythroid cells, leukocytes, and neutrophils. In some embodiments, the activity can include the rate of multiplication of the cell or, where the cell is a quiescent cell, the binding can repress the activation of the quiescent cell. Other embodiments of the present invention are taught herein.
... |
| Apparatus for analyzing particles in urine and method thereof | 20070269897 | 20071122 |
| An apparatus for analyzing particles in urine comprising is disclosed that includes: a measurement specimen preparing section for preparing a measurement specimen by using a urine sample and a stain reagent; an optical detecting section comprising a light source for emitting a light to the prepared measurement specimen, a forward-scattered light receiving element for detecting forward-scattered light emitted from the specimen, a side-scattered light receiving element for detecting side-scattered light emitted from the specimen, and a fluorescence receiving element for detecting fluorescence emitted from the specimen; and a measurement section for measuring leukocytes in urine, based on the forward-scattered light, the side-scattered light and the fluorescence detected by the optical detecting section. A method for analyzing particles in urine is also disclosed.
... |
| Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cdna thereof | 20070270329 | 20071122 |
| Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for the peptide products is also provided, as well as recombinant methods for the production of monocyte chemoattractant products. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.
... |
| Modulators of ms4a gene products | 20070264252 | 20071115 |
| A method of identifying a substance suitable for use in the treatment of a leukocyte-associated inflammatory disease that modulates the activity of a polypeptide encoded by a human MS4A gene. The method involves combining a candidate substance with said polypeptide and measuring the effect of the candidate substance on the activity of said polypeptide. The polypeptide preferably forms a human ion channel, especially a CD20 ion channel.
... |
| Imidazole compounds | 20070265250 | 20071115 |
| Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
... |
| Kinase inhibitors and methods of use thereof | 20070259876 | 20071108 |
| Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.
... |
| Treatment for inflammatory bowel disease | 20070253902 | 20071101 |
| A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.
... |
| Composition comprising platelet-rich plasma | 20070253940 | 20071101 |
| The present invention provides a platelet-rich plasma with high activities in an easy and economical manner. The platelet-rich plasma is obtained by aggregating and precipitating erythrocytes from collected whole blood selectively and facilitatively without employing centrifugation. For example, the plasma is obtained by the addition of a polymer having a residue of an organic phosphate compound. Specifically, the polymer having a residue of an organic phosphate compound can be added to whole blood and allowed to stand for a specific time, thereby to selectively and facilitatively aggregate and precipitate erythrocytes to give a supernatant. The supernatant contains much platelets which exist in their extremely intact state similar as in a living body and simultaneously provides a platelet-rich plasma with high activity comprising much plasma proteins such... |
| Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders | 20070254288 | 20071101 |
| Disclosed herein are methods for determining whether a subject possesses altered pain sensitivity an altered risk of developing acute or chronic pain, or diagnosing a tetrahydrobiopterin (BH4)-related disorder or a propensity thereto. These methods are based on the discovery of GCH1 and KCNS1 allelic variants that are associated with altered pain sensitivity and altered risk of developing acute or chronic pain, and the discovery that a GCH1 “pain protective haplotype” is associated with decreased upregulation of BH4 synthesis in treated leukocytes.
... |
| Blood component processing system, apparatus, and method | 20070255505 | 20071101 |
| A system and method are used in connection with processing of blood components. The processing of blood components may involve centrifugal separation and/or filtering of the blood components. In some examples, at least some blood components are centrifugally separated in a chamber and then filtered via a filter rotating along with a centrifuge rotor, wherein the filter is located closer than the chamber to an axis of rotation of the rotor. The filter may include a porous filtration medium configured to filter leukocytes, platelets, and/or red blood cells. Some examples include a pressure sensor sensing pressure of pumped blood components. The sensed pressure may be used in connection with controlling the pumping of the blood products and/or in connection with determining the location of an interface... |
| Storage and maintenance of blood products including red blood cells and platelets | 20070248941 | 20071025 |
| Cell membrane maintenance of red blood cells and platelet concentrates is improved by the addition of 1 mM-10 mM L-carnitine and derivatives. This improvement allows extension of the period of viability of packed red blood cells and platelet concentrations beyond current periods. Additionally, the materials so treated exhibit extended circulation half life upon transhision to a patient. Improvements in membrane maintenance achieved by this method permit irradiation of sealed containers of blood products so as to substantially sterilize and destroy leukocytes in the same.
... |
| Method for selectively removing virus and leukocytes, removing material and removing apparatus | 20070248942 | 20071025 |
| It is intended to provide a method whereby a virus and leukocytes can be simultaneously eliminated from virus-containing blood and platelets can be recovered at a high yield, and a material and an apparatus therefor. A water-soluble carrier having surface which is capable of capturing a virus and leukocytes in blood but allows the permeation of platelets therethrough is brought into contact with virus-containing blood. Thus the virus and leukocytes can be simultaneously removed from the blood while platelets can be recovered at a high yield.
... |
| Method of treating inflammation | 20070249556 | 20071025 |
| This invention provides methods of preventing and/or treating diseases or conditions associated with inflammation in a mammal, particularly a human. The method comprises administering to a mammal in need thereof an effective amount of a compound of Formula I, IA, or IB, wherein said amount is effective to inhibit inflammation. The invention also provides methods for inhibiting chemotaxis of leukocytes.
... |
| Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis | 20070238094 | 20071011 |
| The present invention includes compositions, systems, arrays and methods for the early detection and consistent determination of SLE using modular analysis of gene expression data.
... |
| Methods and kits for sequentially isolating rna and genomic dna from cells | 20070238118 | 20071011 |
| Methods for obtaining nucleic acid from nucleated cells are disclosed, wherein RNA and fragmented genomic DNA can be sequentially obtained from the same starting material are disclosed. In some embodiments, protein can also be obtained from the same starting material as the RNA and DNA are obtained. According to certain methods, whole blood or a blood fraction comprising nucleated cells is combined with a capture surface and at least some of the leukocytes are retained on the surface. The RNA is released from the retained leukocytes, then the capture surface is treated with a suitable nuclease or other DNA fragmenting agent to release DNA fragments. In certain embodiments, either the released RNA, the released DNA, or both the released RNA and the released DNA are employed... |
| Medicament containing natural leucotriene inhibitors singly or in combination with bioavailable organic selenium supplement for hyperproliferative dermatological conditions and therapeutic methods thereof | 20070231345 | 20071004 |
| The current invention discloses a medicament and its use in a method for therapeutically managing hyperproliferative diseases of the skin in particular, psoriasis of the skin, scalp and nails. The medicament includes a dual inhibitor of 5-lipoxygenase and human leukocyte elastase singly or in combination with a bioavailable organic selenium nutritional supplement. In particular, the medicament includes (a) an oral formulation of acetyl-11-keto-beta-boswellic acid in combination with a bioavailable organic selenium supplement dispersed in a pharmaceutical carrier; and (b) a topical formulation of acetyl-11-keto-beta-boswellic acid alone dispersed in a pharmaceutical carrier. The said medicament is shown to be effective for the therapeutic management of clinical psoriasis based on its ability to (i) provide relief of clinical symptoms and (ii) the ability to clear psoriatic lesions as... |
| Module-level analysis of peripheral blood leukocyte transcriptional profiles | 20070231816 | 20071004 |
| The present invention includes an apparatus, system and method for the development and use of transcriptional modules by obtaining individual gene expression levels from cells obtained from one or more patients with a disease or condition; recording the expression value for each gene in a table that is divided into clusters; iteratively selecting gene expression values for one or more transcriptional modules by: selecting for the module the genes from each cluster that match in every disease or condition; removing the selected genes from the analysis; and repeating the process of gene expression value selection for genes that cluster in a sub-fraction of the diseases or conditions; and iteratively repeating the generation of modules.
... |
| Method and apparatus for measuring hematological sample | 20070231913 | 20071004 |
| A measuring method and a measuring apparatus which can classify and count myeloblast more precisely without influence of other component in a sample including platelet aggregation in measurement of a blood sample with a flowcytometry, wherein damage is given to a cell membrane of erythrocyte and mature leukocyte contained in a hematological sample, a hemocyte in which a cell membrane is damaged is constricted, and this is dyeing-treated with a fluorescent dye which can stain a nucleic acid to obtain a sample, the sample is measured with a flowcytometer, and a cell contained in a first cell group containing myeloblast, which is specified based on forward scattered light information and side scattered light information, and contained in a second cell group containing myeloblast, which is specified... |
| Method of treating pancreatitis | 20070232525 | 20071004 |
| The present invention provides a method of treating pancreatitis comprising administering to a human in need thereof an effective amount of hemin. The administration of hemin is preferably parenteral. In another aspect, the present invention provides a method of pancreatitis prophylaxis comprising administering to a human in need thereof an effective amount of hemin. In a still further aspect, the present invention contemplates a method of inducing an HO gene comprising administering to a human in need thereof an HO-inducing effective amount of hemin. Preferably, the HO gene is the HO-1 gene. In a still further aspect, the present invention contemplates a method of inducing an HO gene in leukocytes for recruitment to the pancreas to treat pancreatitis comprising administering to a human in need thereof... |
| Device and method for high-throughput quantification of mrna from whole blood | 20070224631 | 20070927 |
| Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
... |
| Device and method for high-throughput quantification of mrna from whole blood | 20070224632 | 20070927 |
| Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
... |
| Dna encoding the human serine protease eos | 20070218026 | 20070920 |
| Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease EOS mRNA is expressed in platelets and leukocytes and more specifically eosinophils. Although this protease is abundantly expressed in ovary, retina and stomach, where it may perform important functions, its expression in platelets and certain cells of the immune system suggests that it may play roles in thrombosis and in the immune process. Enzymatically active protease EOS is amenable to further biochemical analyses for the identification of physiological substrates and specific modulators
... |
| Blood co-processing for contingent autologous leukocyte transplantation | 20070212674 | 20070913 |
| A process for producing a leukocyte bank suitable for CAT therapy comprising the steps of providing a blood sample from a healthy donor individual; selectively separating and collecting leukocytes from the sample; selectively separating and collecting red blood cells and/or platelets and/or plasma from the sample; and cryogenically preserving the leukocytes (and optionally the red blood cells and/or platelets and/or plasma); wherein steps are conducted with an automated leukapheresis device comprising a separation device (e.g. a centrifuge rotor or filter), a leukapheresis tubing set and one or more pumps for conveying the sample through the tubing set and the separated leukocytes into a collection vessel.
... |
| Method for treating autoimmune diseases and compositions therefor | 20070207128 | 20070906 |
| A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fcγ receptor-specific complex or a complex which results in the co-crosslinking of Fcγ-chains for treating the leukocytes and/or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fcγ receptor-specific complex and/or complex which results in the co-crosslinking of Fcγ-chains is used to treat a biological sample comprising leukocytes and/or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.
... |
| Therapeutic and diagnostic agents | 20060275313 | 20061207 |
| The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signaling (IRS) molecules and which are expressed by cells of heaematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter alia as diagnostic markers for cells, targets for cell therapy and as validated drug targets in order to modulate the immune response and to treat, prevent and diagnose a range of diseases conditions including cancer, genetic disease, inflammatory conditions and conditions associated with aberrant haematopoietic cell function or activity. The present invention extends to binding partners of the instant molecules such as, for example, antibodies, ligands, adaptor and other signaling associated molecules, agonists and antagonists and... |
| 1,2-di(cyclic) substituted benzene compounds | 20060276465 | 20061207 |
| wherein R10 represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R30, R31 and R32 may be the same or different and each represents hydrogen etc., R40 represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X1 represents CH or nitrogen, and R20, R21, R22 and R23 may be the same or different and each represents hydrogen etc.
... |
| Probes | 20060269916 | 20061130 |
| The present invention relates to probes, methods and apparatus for the detection of the presence or absence of non-contiguous cis-located nucleic acid sequences which are characteristic of alleles including those relating to the human leukocyte antigen (HLA) which is of interest in the field of human transplantation and disease.
... |
| Porous spun polymeric structures and method of making same | 20060261005 | 20061123 |
| A non-woven polymeric matrix for separating leukocytes from a blood sample includes a non-woven three dimensional matrix formed from polymeric fibers having a predetermined pore volume fraction including a defined channel configuration, a predetermined pore size in the range of from about 10 μm to about 250 μm, and a plurality of connections between the plurality of fibers. The matrix is configured so as to remove at least about 98% of leukocytes from at least one unit of packed red blood cells. Methods of making and using the matrix are also provided.
... |
| Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof | 20060263770 | 20061123 |
| Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-4 (alpha and beta) and TREM-5 are disclosed. TREM-4 is a transmembrane glycoprotein expressed selectively in the endothelium of capillaries, in the heart and in the testis. Use of TREM-4 in treatment and diagnosis of various inflammatory diseases and heart diseases and male infertility are also provided. TREM-5 is also a transmembrane glycoprotein expressed selectively in bone marrow-derived population of leukocytes, in particular dendritic cells, and may be upregulated in certain conditions, such as cell activation, inflammation or aberrant dendritic cell function. Blockade of TREM-5 with monoclonal antibodies or soluble TREM-5-HuIgG fusion protein may reduce or block skin... |
| Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals | 20060264357 | 20061123 |
| The present invention provides a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability and at the same time preventing the harmful effects of free radicals on capillaries and surrounding tissues. The method comprises administering to a subject an effective amount of a composition comprising at least one polysaccharide selected from the group of HES, glycogen and dextran of varying molecular sizes and at least one active agent selected from the group consisting of dehydroascorbic acid, von Willebrand Factor, hemoglobin, polysaccharide-conjugated hemoglobin, Cerovive, edaravone, dimethylthiourea, citicoline, poly(ADP-ribose) polymerase inhibitor, oxidant detoxification catalyst, adenosine 2a (A2a) receptor agonist, adenosine 1 (A1) receptor agonist, adenosine, inosine, xanthin oxidase inhibitor, polyethylene-glycol-modified albumin, adenosine triphosphate, histamine,... |
| Method for modulating hla class ii tumor cell surface expression with a cytokine mixture | 20060257357 | 20061116 |
| A method for altering the composition of tumor infiltrating mononuclear cells, increasing CD4+/CD8+ ratio, increasing tumor stroma/epithelial ratio and modulating HLA (Human Leukocyte Antigen) class II expression on a tumor cell surface with a serum-free and mitogen-free mixture having specific cytokine ratios from the group of IL-1β, TNF-α, IFN-γ, GM-CSF, and Interleukin-2 (IL-2) with specific ratios of IL-1β, TNF-α, IFN-γ, GM-CSF to IL-2, respectively. The serum-free and mitogen-free mixtures comprised of cytokine ratios include Leukocyte Interleukin Injection (LI) or Multikine®, which can be further used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.
... |
| Material promoting wound healing | 20060257456 | 20061116 |
| The object of the present invention is to provide a means for utilizing cells that have effects on wound healing as wound-healing promoting materials by efficiently concentrating such cells within a short period of time. The present invention provides a wound-healing promoting material which comprises a sheet-like porous body having on its surface at least leukocytes and/or platelets, a method for producing the same, a device for producing the same, and a method for treating wound sites using the same.
... |
| Sulfonic acids, their derivatives and pharmaceutical compositions containing them | 20060258730 | 20061116 |
| Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chernotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CX-CR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, the selected sulfonic acids and their derivativas are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
... |
| Novel chemokine mimetics synthesis and their use | 20060252687 | 20061109 |
| The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example, and can be selected from a group consisting of hematopoietic stem cells, hematopoietic progenitor cells, primitive granulocytes, primitive erythroid cells, leukocytes, and neutrophils. In some embodiments, the activity can include the rate of multiplication of the cell or, where the cell is a quiescent cell, the binding can repress the activation of the quiescent cell. Other embodiments of the present invention are taught herein.
... |
| Hydrophilized membrane and process for hydrophilization thereof | 20060243657 | 20061102 |
| The present invention relates to a hydrophilized membrane which has greatly suppressed adhesion of blood cells such as erythrocytes, leukocytes and blood platelets within blood, by easily conducting hydrophilization of a hydrophobic porous membrane, and a process for the hydrophilization. The present invention relates to a hydrophilized hydrophobic porous membrane which is obtained by impregnating a medical supply of which the part which comes into contact with blood is hydrophobic in a solution of a substance having surface activity, then rinsing in a solvent into which the surfactant is soluble, and adsorbing an extremely small amount of the substance having surface activity to the surface of the part which comes into contact with blood, wherein the adhesion of blood cells such as erythrocytes, leukocytes and blood... |
| Myeloid colony stimulating factor and uses thereof | 20060247201 | 20061102 |
| The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5- may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
... |
| Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | 20060241132 | 20061026 |
| Since the spiro acid derivatives according to the present invention are excellent in the effect of inhibiting cell adhesion via adhesion molecules, especially adhesion molecule VLA-4, they are useful as therapeutic drugs against various inflammatory diseases. For example, provided are the spiro derivative and the adhesion molecule inhibitor which includes as an active ingredient the spiro derivative as shown by the below formula (18).
... |
| Sp110, a polypeptide component of the nuclear body | 20060234289 | 20061019 |
| Cloning and characterization of a full length cDNA encoding Sp110 (speckled 110), a novel 110 kDa polypeptide, is disclosed. It is disclosed that Sp110 is a component of the nuclear body, is expressed in leukocytes, and is also expressed in other types of cells, including endothelial cells, smooth muscle cells, liver cells and heart cells, after contact with certain cytokines. The disclosure also includes the following: Sp140 recruits Sp110 to the nuclear body, Sp110 functions as an activator of gene transcription, and Sp110 serves as a nuclear hormone receptor co-activator. Sp110 DNAs, polypeptides, antibodies are disclosed. Also disclosed are Sp110-related screening methods and clinical diagnostic methods.
... |
| Detection of surface-associated human leukocyte elastase | 20060234312 | 20061019 |
| In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemoline receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also “binding sites”) on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes... |
| Treatment of osteoarthritis | 20060234921 | 20061019 |
| This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed.
... |
| Systems and methods for collecting leukocyte-reduced blood components, including plasma that is free or virtually free of cellular blood species | 20060229547 | 20061012 |
| Systems and methods collect leukocyte reduced blood components, including plasma that is free or virtually free of cellular blood species, such as red blood cells, platelets, and leukocytes.
... |
| 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | 20060223842 | 20061005 |
| Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2-membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
... |
| Cyclic peptides as g-protein-coupled receptor antagonists | 20060217530 | 20060928 |
| The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.
... |
| Filter for the separation of leukocytes from whole blood or blood preparations, method for production of said filter, corresponding device and use thereof | 20060207937 | 20060921 |
| The invention relates to a filter for the separation of leukocytes from whole blood, comprising a hydrophobic support material and a polymeric coating material, whereby the surface of the filter has a critical surface wetting tension in the range 50 to 80 dyn/cm and the polymeric coating material may be obtained by polymerisation reaction of mixtures comprising hydrophobic and hydrophilic monomers. The invention further relates to a method for production of said filter and devices for the separation of leukocytes from whole blood and the use of the filter.
... |
| Treatment for multiple sclerosis | 20060198822 | 20060907 |
| It is disclosed herein that particular forms of MS have significant pathogenetic differences both between each other and when compared to controls. In particular, CD127 is under-expressed in one form of MS but over-expressed in another form, relative both to each form of MS and to controls. Methods and compositions are provided for the treatment and/or diagnosis of disease caused by forms of multiple sclerosis that under-express and forms that over-express CD127. In specific examples, the methods for treating CD127-low MS comprise administering an effective amount of IL-7 or an effective amount of leukocytes treated with IL-7. Also provided are methods for treating CD127-low MS wherein leukocytes are induced to express at least one receptor, a subunit of which is CD127.
... |
| Device and method for high-throughput quantification of mrna from whole blood | 20060199212 | 20060907 |
| Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
... |
| Modulators of leukocyte activation, compositions and methods of use | 20060199218 | 20060907 |
| The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.
... |
| Methods and kit for diagnosing tick borne illnesses | 20060194267 | 20060831 |
| ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, leukocyte function associated antigens, immunodominant antigens, variable major proteins, and peptides from decorin-binding proteins of Borrelial subspecies (B. sensu stricto. B. afzelii, B. garinii) were used. Antibodies against specific peptides from Babesia and Ehrlichia were also measured.
... |
| X-ray guided drug delivery | 20060188442 | 20060824 |
| A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations thereof, exposing the target tissue to the ionizing radiation. The delivery vehicle includes the active agent and delivers the agent to the target tissue. Representative delivery vehicles include platelets; leukocytes; proteins or peptides which bind activated platelets; antibodies which bind activated platelets; microspheres coated with proteins or peptides which bind activated platelets; liposomes conjugated to proteins or peptides, platelets, or leukocytes which bind activated platelets, or antibodies which bind activated platelets; and combinations thereof.
... |
| Filter for the depletion of leukocytes from blood products | 20060180542 | 20060817 |
| A filter device for the depletion of the leukocyte content from blood products including two or more porous elements each made of one or more layers or filtering materials, wherein said porous elements are arranged in the filter device according to decreasing hydrophilicity, from inlet to outlet, of the filtering material constituting said elements.
... |
| Atp diphosphohydrolase (cd39) gene therapy for inflammatory or thrombotic conditions and transplantation and means there for | 20060182733 | 20060817 |
| A method to render endothelial cells capable of inhibiting platelet and leukocyte-mediated injury and inflammation is described, comprising genetically modifying the cells by inserting DNA encoding ecto-ATP diphosphohydrolase or an oxidation-resistant analog thereof, and expressing a protein having functional ecto-ATP diphosphohydrolase activity, such as the human CD39 protein, by said cells under cellular activating conditions. The method, which can be carried out in vivo, ex vivo or in vitro, has use in allogeneic or xenogeneic transplantation as well as to treat systemic or local inflammatory conditions characterized by platelet aggregation leading to thrombus formation.
... |
| Modulation of plasma membrane human leukocyte elastase | 20060183214 | 20060817 |
| A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein.
... |
| Method for removing leukocytes, leukocyte-removing filter and utilization thereof | 20060184085 | 20060817 |
| It is intended to provide a method for removing leukocytes whereby leukocytes can be removed at a higher level of performance in a short filtration time without clogging. A method comprising passing a leukocyte-containing liquid through a filter for removing leukocytes made of a nonwoven fabric having an average fiber diameter of from 0.3 to 3.0 μm and thus removing the leukocytes from the leukocyte-containing liquid to give a leukocyte-free liquid, characterized by using a nonwoven fabric having a formation index (y) of 50 or less corresponding to a thickness of 0.3 mm; use of a leukocyte removal filter therefor; and the leukocyte removal filter.
... |
| Lysing reagent, cartridge and automatic electronic cell counter for simultaneous enumeration of different types of white blood cells | 20060177347 | 20060810 |
| The present invention relates to a lysing reagent for use in the simultaneous automatic electronic enumeration and volumetric discrimination of different types of blood cells, such as leukocytes, thrombocytes, etc, in blood. Further, the present invention relates to a Coulter (impedance) counting apparatus containing the lysing reagent, for example a Coulter counting apparatus with a disposable cartridge for characterizing cells suspended in a liquid, especially a self-contained disposable cartridge for single-use analysis, such as for single-use analysis of a small quantity of whole blood.
... |
